SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Posted inDiabetes & Endocrinology Neurology news

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective confirmation.
Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately controlled by dual therapy.
Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet
Posted inClinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology strategy for diabetes prevention.
Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent alone or placebo.
Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial
Posted inClinical Updates OB/GYN & Women's Health Oncology Specialties

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tumor hypoxia assessments.
Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
Posted inOB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.